Baird Affirms Sarepta Therapeutics (SRPT) at 'Outperform'; Incrementally Positive on PTAB Decision (BMRN)

September 21, 2016 6:26 AM EDT
Get Alerts SRPT Hot Sheet
Price: $59.10 -0.94%

Rating Summary:
    16 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 12 | New: 15
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Baird is incrementally positive on the PTAB ruling for Sarepta Therapeutics, Inc. (NASDAQ: SRPT), which was announced late Tuesday.

Analyst Brian Skorney commented today, Though the dominant story last year was the battle for approval between eteplirsen and BioMarin's (Nasdaq: BMRN) drisapersen, after BioMarin's rejection and discontinuation of the antisense programs for DMD, the story shifted to patent litigation, interferences, and potential for royalties. Earlier today, PTAB issued a decision on the final patent interference, handing Sarepta its second win in two days. Though the decisions can be appealed, it looks like Sarepta may avoid paying royalties to BMRN in the U.S.

Baird has Sarepta at Outperform with a price target of $102.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Litigation

Related Entities

Robert W Baird

Add Your Comment